NCT04659421View on ClinicalTrials.gov

Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 3, 2020

Primary Completion Date

July 1, 2023

Study Completion Date

July 20, 2023

Conditions
Low-grade GliomaPediatric Brain Tumor
Interventions
DRUG

combined therapy with rh-ES and CV

"All the patients receive combined therapy with recombinant human endostatin and traditional weekly CV regimen.~Carboplatin is administered at a dose of 220 mg/m2. Vincristine is administered at a dose of 1.5 mg/m2 (maximum dose 2 mg). Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks."

Trial Locations (1)

Unknown

Capital Medical University Sanbo Brain Hospital, Beijing

All Listed Sponsors
lead

Beijing Sanbo Brain Hospital

OTHER

NCT04659421 - Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas | Biotech Hunter | Biotech Hunter